Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PanACEA-STEP2C-01: Novel and Optimized Regimens for Pulmonary TB
NCT05807399Phase 2Recruiting
- Start
- Apr 2023
- Primary completion
- Oct 2027
- Modality
- Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of BTZ-043, alpibectir, ganfeborole and delpazolid in pulmonary tuberculosis (TB) (7 arms). Primary endpoints: Time to stable culture conversion to negative in liquid media and Change in Mycobacterial load. Started Apr 2023; status: recruiting.
02
Drugs
BTZ-043alpibectirganfeboroledelpazolid
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT05807399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05807399.